Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.

BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.

2.

Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.

Fossati N, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Lughezzani G, Gadda GM, Lista G, Larcher A, Abrate A, Mistretta F, Bini V, Redorta JP, Graefen M, Guazzoni G.

BJU Int. 2015 Jun;115(6):913-20. doi: 10.1111/bju.12718. Epub 2015 Mar 26.

3.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.

PMID:
23375961
4.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
5.

Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.

Mearini L, Ferri C, Lazzeri M, Bini V, Nunzi E, Fiorini D, Costantini E, Manasse GC, Porena M.

Urol Int. 2014;93(2):135-45. doi: 10.1159/000356240. Epub 2014 Apr 8.

PMID:
24732975
6.

Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.

Abrate A, Lazzeri M, Lughezzani G, Buffi N, Bini V, Haese A, de la Taille A, McNicholas T, Redorta JP, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Freschi M, Guazzoni G.

BJU Int. 2015 Apr;115(4):537-45. doi: 10.1111/bju.12907.

7.

Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A.

Clin Chem. 2013 Jan;59(1):306-14. doi: 10.1373/clinchem.2012.195784. Epub 2012 Dec 4.

8.

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F.

Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.

PMID:
22078333
9.

Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.

Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F, Lista G, Fossati N, Larcher A, Kinzikeeva E, Buffi N, Dell'Acqua V, Bini V, Montorsi F, Guazzoni G.

Urology. 2014 Mar;83(3):606-12. doi: 10.1016/j.urology.2013.10.016. Epub 2013 Dec 6.

PMID:
24315305
10.

Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.

Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.

PMID:
25139197
11.

Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.

Na R, Ye D, Liu F, Chen H, Qi J, Wu Y, Zhang G, Wang M, Wang W, Sun J, Yu G, Zhu Y, Ren S, Zheng SL, Jiang H, Sun Y, Ding Q, Xu J.

Prostate. 2014 Nov;74(15):1569-75. doi: 10.1002/pros.22876. Epub 2014 Aug 31.

PMID:
25176131
12.

Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.

Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, Lista G, Cestari A, Buffi N, Bini V, Freschi M, Rigatti P, Montorsi F, Guazzoni G.

J Urol. 2012 Oct;188(4):1137-43. doi: 10.1016/j.juro.2012.06.017. Epub 2012 Aug 15.

PMID:
22901578
13.
14.

Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

Eminaga O, Bögemann M, Breil B, Titze U, Wötzel F, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Nov;32(8):1317-26. doi: 10.1016/j.urolonc.2014.04.018. Epub 2014 Jun 2.

PMID:
24893699
15.

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D.

PLoS One. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. Print 2013.

16.

The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.

Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS.

Int Urol Nephrol. 2014 Apr;46(4):711-7. doi: 10.1007/s11255-013-0582-0. Epub 2013 Oct 18.

PMID:
24136184
17.

Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.

Huang YQ, Sun T, Zhong WD, Wu CL.

Am J Clin Exp Urol. 2014 Dec 25;2(4):343-50. eCollection 2014. Review.

18.

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.

Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D.

Prostate. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20.

PMID:
22821756
19.

Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.

Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, Randone D, Abdollah F, Capitanio U, Larcher A, Lista G, Gadda GM, Bini V, Montorsi F, Guazzoni G.

J Urol. 2013 Aug;190(2):496-501. doi: 10.1016/j.juro.2013.02.3184. Epub 2013 Mar 1.

PMID:
23466239
20.

Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.

Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G, Lazzeri M.

Korean J Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub 2014 Jul 11. Review.

Items per page

Supplemental Content

Write to the Help Desk